» Articles » PMID: 36952486

Recruitment Strategies and HPV Self-collection Return Rates for Under-screened Women for Cervical Cancer Prevention

Overview
Journal PLoS One
Date 2023 Mar 23
PMID 36952486
Authors
Affiliations
Soon will be listed here.
Abstract

In the United States, medically underserved women carry a heavier burden of cancer incidence and mortality, yet are largely underrepresented in cancer prevention studies. My Body, My Test is a n observational cohort, multi-phase cervical cancer prevention study in North Carolina that recruited low-income women, aged 30-65 years and who had not undergone Pap testing in ≥ 4 years. Participants were offered home-based self-collection of cervico-vaginal samples for primary HPV testing. Here, we aimed to describe the recruitment strategies utilized by study staff, and the resulting recruitment and self-collection kit return rates for each specific recruitment strategy. Participants were recruited through different approaches: either direct (active, staff-effort intensive) or indirect (passive on the part of study staff). Of a total of 1,475 individuals screened for eligibility, 695 were eligible (47.1%) and 487 (70% of eligible) participants returned their self-collection kit. Small media recruitment resulted in the highest number of individuals found to be study eligible, with a relatively high self-collection kit return of 70%. In-clinic in-reach resulted in a lower number of study-eligible women, yet had the highest kit return rate (90%) among those sent kits. In contrast, 211 recruitment which resulted in the lowest kit return of 54%. Small media, word of mouth, and face-to-face outreach resulted in self-collection kit return rates ranging from 72 to 79%. The recruitment strategies undertaken by study staff support the continued study of reaching under-screened populations into cervical cancer prevention studies.

Citing Articles

The Acceptability and Feasibility of Self-Collected HPV Testing for Cervical Cancer Screening Among Black and Latinx Women in Chicago: Perspectives from the Community.

Glass-Riveros E, Baumann K, Craemer K, Geller S, Nava Frenier M, McDonald J Womens Health Rep (New Rochelle). 2024; 5(1):735-743.

PMID: 39463469 PMC: 11512086. DOI: 10.1089/whr.2024.0102.


Performance of BD Onclarity HPV assay on FLOQSwabs vaginal self-samples.

Martinelli M, Latsuzbaia A, Bonde J, Pedersen H, Iacobone A, Bottari F Microbiol Spectr. 2024; 12(3):e0287223.

PMID: 38323823 PMC: 10913526. DOI: 10.1128/spectrum.02872-23.


Implications of viral infections and oncogenesis in uterine cervical carcinoma etiology and pathogenesis.

Chu D, Liu T, Yao Y Front Microbiol. 2023; 14:1194431.

PMID: 37293236 PMC: 10244558. DOI: 10.3389/fmicb.2023.1194431.

References
1.
Broberg G, Gyrd-Hansen D, Jonasson J, Ryd M, Holtenman M, Milsom I . Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2013; 134(9):2223-30. DOI: 10.1002/ijc.28545. View

2.
Unger J, Gralow J, Albain K, Ramsey S, Hershman D . Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. JAMA Oncol. 2015; 2(1):137-9. PMC: 4824189. DOI: 10.1001/jamaoncol.2015.3924. View

3.
Smith J, Des Marais A, Deal A, Richman A, Perez-Heydrich C, Yen-Lieberman B . Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States. Sex Transm Dis. 2017; 45(1):42-48. PMC: 5846187. DOI: 10.1097/OLQ.0000000000000681. View

4.
Brewster W, Anton-Culver H, Ziogas A, Largent J, Howe S, Hubbell F . Recruitment strategies for cervical cancer prevention study. Gynecol Oncol. 2002; 85(2):250-4. DOI: 10.1006/gyno.2002.6592. View

5.
Weitz T, Freund K, Wright L . Identifying and caring for underserved populations: experience of the National Centers of Excellence in Women's Health. J Womens Health Gend Based Med. 2002; 10(10):937-52. DOI: 10.1089/152460901317193521. View